GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Recruiting now · Phase 1/Phase 2
Conditions studied: Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma, Clear Cell Renal Cell Cancer (ccRCC), Squamous Cell Non Small Cell Lung Cancer
In brief
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or metastatic solid tumors.
Key facts
- Study ID
- NCT04977453
- Run by
- GI Innovation, Inc.
- People needed
- 317
- Starts
- 2021-08-02
- Expected to finish
- 2028-06-30
- Last updated by the study team
- 2026-05-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Korea University Anam Hospital — Seoul, Seongbuk-gu, South Korea (enrolling)
- Ewha Womans University Mokdong Hospital — Seoul, Yangcheon-gu, South Korea (enrolling)
- Tisch Cancer Institute (TCI), Icahn School of Medicine — New York, New York, United States (enrolling)
- Carolina Biooncology Institute — Huntersville, North Carolina, United States (enrolling)
- The Catholic University of Korea Seoul ST.MARY'S Hospital — Seoul, Banpo-daero, South Korea (enrolling)
- Seoul National University Bundang Hospital — Seoul, Bundang-gu, South Korea (enrolling)
- Chungnam National University Hospital — Daejeon, Daejeon, South Korea (enrolling)
- Samsung Medical Center — Seoul, Gangnam, South Korea (enrolling)
- The Catholic University of Korea St. Vincent's Hospital — Suwon, Kyeonggi-do, South Korea (enrolling)
- Yonsei University Health System, Severance Hospital — Seoul, South Korea (enrolling)
- Yonsei University Health System, Severance Hospital — Seoul, South Korea (enrolling)
- Asan Medical Center — Seoul, South Korea (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.